ORCID "Akin Telli, Tugba/0000-0001-6535-6030" WoS İndeksli Yayınlar Koleksiyonu için listeleme
-
The effectiveness and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early-stage human epidermal growth factor receptor 2-positive breast cancer: Turkish Oncology Group study
Özdemir, Özlem; Zengel, Baha; Yıldız, Yaşar; Uluç, Başak Oyan; Çabuk, Devrim; Ozden, Ercan; Alacacıoğlu, Ahmet; Avcı, Okan (Lippincott Williams & Wilkins, 2022)In our study, we aimed to evaluate the pathological response rates and side effect profile of adding pertuzumab to the treatment of HER2+ locally advanced, inflammatory, or early-stage breast cancer. This study was conducted ... -
Real-life comparison of afatinib and erlotinib in non-small cell lung cancer with rare EGFR exon 18 and exon 20 mutations: a Turkish Oncology Group (TOG) study
Gürsoy, Pınar; Tatlı, Ali Murat; Erdem, Dilek; Göker, Erdem; Çelik, Emir; Demirci, Nebi Serkan; Yumuk, Perran Fulden; Çavdar, Eyyüp (Springer, 2022)Objectives To compare the survival of first- and second-generation tyrosine kinase inhibitors (TKIs) in patients with rare EGFR exon 18 and exon 20 mutation-positive non-small cell lung cancer (NSCLC). Materials and methods ...